---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-066032"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2023-11-27T23:59:59+00:00"
generated_at: "2026-06-07T21:28:19.997279+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xenon reports Phase 2 XEN1101 MDD trial misses primary endpoint but hits secondary measures

## Summary
- MADRS at week 6: placebo reduction 13.90; XEN1101 20 mg reduction 16.94 (p=0.135), not statistically significant.
- HAM-D17 (p=0.042) and anhedonia SHAPS (p=0.046) secondary endpoints met statistical significance for 20 mg.
- Early onset: MADRS at week 1 showed significance for 20 mg (p=0.047); CGI-I also significant (p=0.004).
- XEN1101 well tolerated; no SAEs in active arms; common TEAEs: dizziness (17.9%), somnolence (10.7%), headache (8.9%).
- Company exploring future MDD development; XEN1101 also in Phase 3 epilepsy with no titration required.

## SEC filing metadata
- accession: 0000950170-23-066032
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2023-11-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017023066032/0000950170-23-066032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017023066032/xene-20231127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-066032
- JSON: https://secwatch.observer/filing/0000950170-23-066032.json
- Plain text: https://secwatch.observer/filing/0000950170-23-066032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.